Amneal Pharmaceuticals Valuation
| 2DT Stock | EUR 7.30 0.25 3.31% |
At this time, the firm appears to be fairly valued. Amneal Pharmaceuticals shows a prevailing Real Value of €7.58 per share. The current price of the firm is €7.3. Our model approximates the value of Amneal Pharmaceuticals from analyzing the firm fundamentals such as Return On Equity of -0.88, current valuation of 2.95 B, and Profit Margin of (0.06) % as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Amneal Pharmaceuticals' price fluctuation is somewhat reliable at this time. Calculation of the real value of Amneal Pharmaceuticals is based on 3 months time horizon. Increasing Amneal Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Amneal stock is determined by what a typical buyer is willing to pay for full or partial control of Amneal Pharmaceuticals. Since Amneal Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Amneal Stock. However, Amneal Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 7.3 | Real 7.58 | Hype 7.55 |
The real value of Amneal Stock, also known as its intrinsic value, is the underlying worth of Amneal Pharmaceuticals Company, which is reflected in its stock price. It is based on Amneal Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Amneal Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Amneal Pharmaceuticals helps investors to forecast how Amneal stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Amneal Pharmaceuticals more accurately as focusing exclusively on Amneal Pharmaceuticals' fundamentals will not take into account other important factors: Amneal Pharmaceuticals Total Value Analysis
Amneal Pharmaceuticals is presently estimated to have takeover price of 2.95 B with market capitalization of 712.21 M, debt of 2.72 B, and cash on hands of 452.1 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Amneal Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.95 B | 712.21 M | 2.72 B | 452.1 M |
Amneal Pharmaceuticals Investor Information
About 68.0% of the company shares are owned by institutions such as pension funds. The company has Price-to-Book (P/B) ratio of 1.17. In the past many companies with similar price-to-book ratios have beat the market. Amneal Pharmaceuticals recorded a loss per share of 0.73. The entity had not issued any dividends in recent years. Based on the key indicators related to Amneal Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Amneal Pharmaceuticals is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Amneal Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Amneal Pharmaceuticals has an asset utilization ratio of 53.14 percent. This implies that the Company is making €0.53 for each dollar of assets. An increasing asset utilization means that Amneal Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Amneal Pharmaceuticals Ownership Allocation
Amneal Pharmaceuticals holds a total of 151.48 Million outstanding shares. Over half of Amneal Pharmaceuticals' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Amneal Pharmaceuticals. Please watch out for any change in the institutional holdings of Amneal Pharmaceuticals as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Amneal Pharmaceuticals Profitability Analysis
The company reported the revenue of 2.09 B. Net Income was 10.62 M with profit before overhead, payroll, taxes, and interest of 783.95 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Amneal Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Amneal Pharmaceuticals and how it compares across the competition.
About Amneal Pharmaceuticals Valuation
The stock valuation mechanism determines Amneal Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Amneal Pharmaceuticals. We calculate exposure to Amneal Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Amneal Pharmaceuticals's related companies.Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey. AMNEAL PHMCTCLS operates under Drug ManufacturersSpecialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 6000 people.
8 Steps to conduct Amneal Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Amneal Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Amneal Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Amneal Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Amneal Pharmaceuticals' revenue streams: Identify Amneal Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Amneal Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Amneal Pharmaceuticals' growth potential: Evaluate Amneal Pharmaceuticals' management, business model, and growth potential.
- Determine Amneal Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Amneal Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Amneal Stock analysis
When running Amneal Pharmaceuticals' price analysis, check to measure Amneal Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals is operating at the current time. Most of Amneal Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals' price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |